Biotechnological companies using AI
IGC Pharma, Inc. (NYSE American: IGC), a clinical--stage pharmaceutical company, announced on January 22, 2026, the addition of Integrative Clinical Trials, LLC as a new clinical site for its Phase 2 CALMA clinical trial. The trial is evaluating IGC--AD1 for the treatment of agitation associated with Alzheimer's disease. IGC Pharma is leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, and this expansion strengthens the trial's network and is expected to support patient enrollment and diversity.